BPC-157: what the studies really show

A synthetic fragment of a stomach protein

BPC-157 is a chain of 15 amino acids (GEPPPGKPADDAGLV), made in a lab (FDA PCAC briefing, July 2026). It is described as a piece of a larger protein found in human gastric juice. Its molecular targets in the body have not been identified (FDA PCAC briefing, July 2026).

In rats it raised blood vessel density. In human vascular cells grown in a dish it increased levels of VEGFR2, a receptor involved in growing new blood vessels (Hsieh et al. 2017). Whether any of that translates to people injecting or swallowing it is unknown.

Six studies, about 84 people, zero using the popular routes

Six published reports have given BPC-157 to people: the five clinical studies FDA reviewed, covering about 81 people (FDA PCAC briefing, July 2026), and a 2026 dental case report with 3 more (Froum 2026). None used subcutaneous or oral dosing. A 2026 systematic review of the human evidence for musculoskeletal use found only 3 studies covering 30 participants, and rated the certainty of evidence "very low" (Poolton et al. 2026).

Enema in healthy men (2002/2003). A placebo-controlled study randomized 32 men (24 got BPC-157, 8 placebo) to receive a rectal enema at doses of 0.25 to 2 mg/kg. Each subject got one dose, a one-week washout, then daily doses for 7 days. Headache and flatulence occurred about as often on placebo. Plasma levels were mostly below the assay limit, meaning absorption from the enema was too low to measure reliably. This study was never published beyond meeting abstracts (FDA PCAC briefing, July 2026).

Enema in ulcerative colitis (2005). A multicentre double-blind trial randomized 53 people with mild to moderate UC, 1:1, to an 80 mg daily enema or placebo for 2 weeks. The BPC-157 group improved by 3.2 points on a disease activity index; the placebo group improved by 1.6 points. The 1.6 point difference was not statistically significant (95% confidence interval: negative 4.84 to positive 1.62). FDA reviewed these data in July 2026 and called them "inadequate" (FDA PCAC briefing, July 2026). This trial, too, exists only as a meeting abstract. The Zagreb group lists the compound (then called PL 14736, developed by Pliva) as having reached clinical phase 2 for inflammatory bowel disease (Sikirić 2012). It was never published in full.

Knee injections (2021). A retrospective chart review from one Florida clinic. 17 patients got intra-articular BPC-157 (2 to 4 mg, one or two injections), 4 of them together with thymosin beta-4. 16 were reached by phone 6 to 12 months later, and 14 reported relief. No control group, no imaging, no validated pain scale (Lee and Padgett 2021).

Bladder injections (2024). 12 women with interstitial cystitis received 10 mg of BPC-157 injected into the bladder wall during a single cystoscopy (1 mg at each of 10 sites). All 12 rated themselves 5 out of 5 on a global response scale. No control group (Lee, Walker and Ayadi 2024).

Intravenous pilot (2025). Two people (both had received IV BPC-157 before) got 10 mg on day 1 and 20 mg on day 2. Heart, liver, kidney, thyroid, and glucose labs did not change. No adverse events (Lee and Burgess 2025).

Dental nerve injury (2026). Three patients with nerve damage after dental surgery received BPC-157 injected inside the mouth once a week for 4 weeks. Each injection also contained TB-500, ARA-290, dexamethasone, and bupivacaine. Sensation improved, but the authors say causality cannot be established because five drugs were given together (Froum 2026).

Most of the data is animal work from one lab

The bulk of BPC-157 research is in rodents. A systematic review of the orthopedic literature to June 2024 found 35 preclinical studies and just 1 clinical study (Vasireddi et al. 2025).

In our PubMed count on 3 November 2026, Predrag Sikirić of the University of Zagreb is an author on 176 of 236 BPC-157 papers (75%). Among non-review papers his share is 80%. Among animal-only papers, 87%. Independent work is limited to a few groups in Taiwan, China, and Turkey. That is a thin base of independent replication for a peptide promoted this widely.

Not approved anywhere, and the US status keeps shifting

BPC-157 is not approved as a medicine in any country and appears in no pharmacopoeia (FDA PCAC briefing, July 2026). FDA had placed it in Category 2, a list of substances that may pose significant safety risks for compounding. By April 2026 it was moved to "nominated but withdrawn" on that list (FDA Category 2 page, April 2026).

At the Pharmacy Compounding Advisory Committee on 23 July 2026, FDA scientists reviewed all human and animal data, evaluated BPC-157 for ulcerative colitis, and recommended against adding it to the 503A Bulks List (FDA PCAC briefing, July 2026). On 30 October 2026, HHS announced a draft policy not to act against pharmacies that compound certain peptides while the 503A list is still being built through rulemaking (HHS enforcement-discretion notice, October 2026).

BPC-157 is also prohibited at all times under WADA's S0 category (non-approved substances) on the 2026 Prohibited List (WADA 2026 Prohibited List). Athletes subject to anti-doping rules cannot use it.

Doses used in the studies

Every human study used a different route, and none used subcutaneous or oral dosing. Enema: 0.25 to 2 mg/kg, one dose and then daily for 7 days, in healthy men, and 80 mg daily for 2 weeks in UC (FDA PCAC briefing, July 2026). Knee: 2 to 4 mg, one or two injections (Lee and Padgett 2021). Bladder wall: 10 mg total in one procedure (Lee, Walker and Ayadi 2024). IV: 10 mg on day 1, 20 mg on day 2 (Lee and Burgess 2025). Inside the mouth: 1 mg weekly for 4 weeks, alongside four other drugs (Froum 2026).

An oral phase 1 registered in 2015 planned single doses of 1 to 6 mg, then 3 mg every 8 hours for 2 weeks. It never reported results (NCT02637284). A study of BPC-157 gummies (500 micrograms per serving, two daily for 8 weeks, 40 people, no control group) was completed in late 2025 and has posted no data (NCT07752381).

Safety: no red flags yet, but almost no data to find them

No serious adverse events were reported in the roughly 84 people who received BPC-157 in published research, but FDA notes that most studies gave little detail on how safety was monitored (FDA PCAC briefing, July 2026). In the enema studies, headache and flatulence were about as common on placebo. In the colitis trial, 3 people on BPC-157 and 2 on placebo dropped out for adverse events, mostly worsening of their colitis.

FDA's adverse event database held 3 reports for injected BPC-157 products through December 2025: injection-site redness (in someone also injecting thymosin), shortness of breath requiring an ER visit, and skin and gum darkening that came back when a BPC-157 plus TB-500 product was restarted (FDA PCAC briefing, July 2026). FDA could not confirm whether BPC-157 caused any of these.

What nobody knows. The longest daily human exposure is 2 weeks of enemas. The longest animal toxicity study FDA found lasted 28 days. In those 28-day studies (rats and dogs), researchers saw changes in clotting times and liver markers (FDA PCAC briefing, July 2026). There are no carcinogenicity studies. BPC-157 promotes blood vessel growth in animals, so whether it could promote tumor growth is an open question with no data either way. FDA also flags immunogenicity risk for injected peptides, especially when products contain aggregates or impurities.

The half-life in rats and dogs was under 30 minutes after IV or IM dosing (He et al. 2022). No usable human pharmacokinetic data exist. Plasma levels after the rectal studies were mostly below the detection limit (FDA PCAC briefing, July 2026). Product quality is another unknown: FDA described the substance as "not well characterized," and a doping laboratory has identified BPC-157 in confiscated vials (FDA PCAC briefing, July 2026; Cox et al. 2017).

Where the evidence stands

BPC-157 has a large animal literature, most of it from one lab. In published research, about 84 people have received it: roughly 50 in two enema studies that were never fully published (and the one that tested a disease did not beat placebo) and roughly 34 in small, uncontrolled reports using routes that do not match how the peptide is commonly used.

No published human study has tested subcutaneous or oral BPC-157. The animal data may be worth following up, but they do not show that injecting or swallowing this peptide does anything in a human body. A placebo-controlled trial of subcutaneous BPC-157 for 90 days after rotator-cuff surgery (30 planned) could start answering that question, but it is not yet recruiting (NCT07803250).

Sources

1. FDA PCAC briefing document, BPC-157, July 2026. FDA review of all available human studies, adverse events, and animal toxicology for BPC-157 (free base and acetate).
2. Hsieh et al. 2017. BPC-157 increased vessel density in rats and raised VEGFR2 in human vascular cells in a dish.
3. Froum 2026. Three case reports: intraoral BPC-157 with four other drugs for dental nerve injury.
4. Poolton et al. 2026. Systematic review of human BPC-157 evidence for musculoskeletal conditions: 3 studies, 30 people, certainty very low.
5. Sikirić 2012. Review by the Zagreb group listing BPC-157 (PL 14736) as having reached clinical phase 2.
6. Lee and Padgett 2021. Retrospective chart review: 17 patients, intra-articular BPC-157 for knee pain, one Florida clinic.
7. Lee, Walker and Ayadi 2024. Single-arm pilot: BPC-157 injected into the bladder wall in 12 women with interstitial cystitis.
8. Lee and Burgess 2025. IV safety pilot in 2 people.
9. Vasireddi et al. 2025. Systematic review of BPC-157 in orthopedics: 35 preclinical and 1 clinical study.
10. FDA Category 2 page, April 2026. BPC-157 listed under "nominated but withdrawn."
11. HHS enforcement-discretion notice, October 2026. Draft policy covering certain compounded peptides while 503A rulemaking continues.
12. WADA 2026 Prohibited List. BPC-157 named under S0, prohibited at all times.
13. NCT02637284. Oral phase 1 in healthy volunteers, registered 2015, status unknown, never reported.
14. NCT07752381. Open-label study of BPC-157 gummies: 40 people, completed November 2025, no results posted.
15. He et al. 2022. Pharmacokinetics of BPC-157 in rats and beagle dogs.
16. Cox et al. 2017. A doping lab identified BPC-157 in confiscated vials and built a urine test for it.
17. NCT07803250. Planned subcutaneous BPC-157 trial after rotator-cuff repair: 30 participants, not yet recruiting.